Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dib, M.
Right arrow Articles by Bousser, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dib, M.
Right arrow Articles by Bousser, M. G.
Related Collections
Right arrow All Headache
Right arrow Migraine
Right arrow All Clinical trials
Right arrow Clinical trials Randomized controlled (CONSORT agreement)

Neurology 2002;58:1660-1665
© 2002 American Academy of Neurology

Efficacy of oral ketoprofen in acute migraine

A double-blind randomized clinical trial M. Dib, MD, H. Massiou, MD, M. Weber, MD, P. Henry, MD, S. Garcia–Acosta, PhD and M. G. Bousser, MD and the Bi-Profenid Migraine Study Group

* See the Appendix on page 1664 for a list of participating investigators in the Bi-Profenid Migraine Study Group.
From the Laboratoire Aventis (Drs. Dib and Garcia–Acosta), Paris; Service de Neurologie (Drs. Massiou and Bousser), Hôpital Lariboisière, AP-HP, Paris; CHU–Service de Neurologie (Dr. Weber), Bâtiment Neurologique, Nancy; and Service de Neurologie (Dr. Henry), Hôpital Pellegrin–Tripode, Bordeaux, France.

Address correspondence and reprint requests to Dr. M.G. Bousser, Service de Neurologie, Hôpital Lariboisière, 2 rue Ambroise Paré, 75475 Paris Cedex, France; e-mail: mg.bousser{at}lrb.ap-hop-paris.fr

:Background Certain nonsteroidal anti-inflammatory drugs are effective in the acute treatment of migraine attacks. The authors report a double-blind, placebo-controlled, randomized cross-over trial of a dual-release formulation of oral ketoprofen in the acute treatment of migraine attacks.

Methods: The authors compared the efficacy of two doses of ketoprofen (75 or 150 mg) with that of placebo (primary analysis) and zolmitriptan 2.5 mg (secondary analysis) on one to four consecutive attacks in 235 intent-to-treat patients (out of 257 randomized patients) with migraine with or without aura. The principal efficacy outcome was headache relief (reduction in headache severity from severe or moderate to mild or absent at 2 hours).

Results: Results are based on 838 attacks with a severe or moderate headache that were evaluable at 2 hours. Relief was reported for 62.6% of headaches treated with ketoprofen 75 mg, 61.6% with ketoprofen 150 mg, and 66.8% with zolmitriptan. The difference between the three active treatments and placebo (27.8% relief) was highly significant, both tests of ketoprofen vs placebo being globally controlled at a 5% level for the type I error (primary analysis). Headaches at 2 hours disappeared more frequently for the active treatments than for placebo. The authors also demonstrated efficacy on most other secondary outcomes. The tolerance of ketoprofen was good (similar to that of placebo).

Conclusions: Oral ketoprofen (75 mg or 150 mg) in a dual-release formulation is an effective and well-tolerated drug in the acute treatment of migraine attacks.




This article has been cited by other articles:


Home page
CephalalgiaHome page
L Vecsei, G Gallacchi, I Sagi, J Semjen, J Tajti, D Szok, M Muller, P Vadass, and M Kerekgyarto
Diclofenac Epolamine is Effective in The Treatment of Acute Migraine Attacks. A Randomized, Crossover, Double Blind, Placebo-Controlled, Clinical Study
Cephalalgia, January 1, 2007; 27(1): 29 - 34.
[Abstract] [Full Text] [PDF]


Home page
CephalalgiaHome page
H-C Diener, P Montagna, G Gacs, P Lyczak, G Schumann, B Zoller, L. Mulder, J Siegel, K Edson, and on behalf of the Study Group*
Efficacy and Tolerability of Diclofenac Potassium Sachets in Migraine: A Randomized, Double-Blind, Cross-Over Study in Comparison with Diclofenac Potassium Tablets and Placebo
Cephalalgia, May 1, 2006; 26(5): 537 - 547.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
C. Waeber and M. A. Moskowitz
Migraine as an inflammatory disorder
Neurology, May 24, 2005; 64(10_suppl_2): S9 - S15.
[Full Text] [PDF]


Home page
CephalalgiaHome page
T. EMSASI, H. Diener, G Bussone, H de Liano, A Eikermann, R Englert, T Floeter, V Gallai, H Gobel, E Hartung, et al.
Placebo-Controlled Comparison of Effervescent Acetylsalicylic Acid, Sumatriptan and Ibuprofen in the Treatment of Migraine Attacks
Cephalalgia, November 1, 2004; 24(11): 947 - 954.
[Abstract] [Full Text] [PDF]


Home page
CephalalgiaHome page
R. Lipton, M. Bigal, and P. Goadsby
Double-Blind Clinical Trials of Oral Triptans Vs Other Classes of Acute Migraine Medication -- A Review
Cephalalgia, May 1, 2004; 24(5): 321 - 332.
[Abstract] [Full Text] [PDF]